Skip to main content

Market Overview

Analyst Points At 3 Upcoming Biotech Lock-Up Expirations


Lock-ups on three biotech companies will expire later this quarter and an analyst warned that their shares could then lag the market.

Cantor Fitzgerald's Mara Goldstein said that following lockup expirations, companies in the sector on average underperform the Nasdaq Biotechnology Index by about 25 percent in the ensuing 30 days.

Xenon Pharmaceuticals Inc (NASDAQ: XENE)'s lock-up on nearly 62 percent of its shares outstanding expires May 3. The company went public in November and its shares have since gained about 62 percent.

Juno Therapeutics Inc (NASDAQ: JUNO) will see a lock-up on 85 percent of its shares outstanding expire June 16. The company's shares have gained about 84 percent since its initial public offering in December.

Cellectis SA (ADR) (NASDAQ: CLLS)'s lock-up on 36 percent of its shares outstanding expires June 22. Its shares are off about 18 percent since its March 26 IPO.

Goldstein said that 92 biotech or specialty drug companies with relatively recent lockup expirations gained an average of 3 percent in the subsequent 30 days, versus an average gain of 4 percent during the same periods for the Nasdaq Biotechnology Index.

In a more general roundup of recent biotech performance, Goldstein said small-cap oncology companies have gained an average of 11 percent and seen the strongest stock performance among the group during the quarter-to-date.

Gains in the subsector during the past two weeks have been lead by Curis, Inc. (NASDAQ: CRIS), Exelixis, Inc.(NASDAQ: EXEL), Heat Biologics Inc (NASDAQ: HTBX) and Synta Pharmaceuticals Corp. (NASDAQ: SNTA), according to Goldstein.

Latest Ratings for XENE

Oct 2020SVB LeerinkInitiates Coverage OnOutperform
Jul 2020NeedhamInitiates Coverage OnBuy
Jun 2020JefferiesAssumesBuy

View More Analyst Ratings for XENE
View the Latest Analyst Ratings


Related Articles (XENE + JUNO)

View Comments and Join the Discussion!

Posted-In: Cantor Fitzgerald Mara GoldsteinAnalyst Color Biotech News Analyst Ratings Trading Ideas General

Latest Ratings

FSRMorgan StanleyMaintains40.0
MEDDA DavidsonMaintains302.0
VICRBWS FinancialMaintains120.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at